Skip to content
Biodatica
Start free

Sanofi

Germany, Aichi-ken

OncologyFiled/ApprovedListed · SNY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Filed/Approved trial registered: iGlarLixi CGM Study in Chinese T2D Individuals After OADs

4mo agoTrial registeredMar 17, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Dec 10, 2024

    Type 2 Diabetes (T2D) · RECRUITING · sponsor: Sanofi · iGlarLixi CGM Study in Chinese T2D Individuals After OADs

    ClinicalTrials.gov · NCT06671587 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jan 18, 2023

    Hepatic Function Abnormal · COMPLETED · sponsor: Sanofi · A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

    ClinicalTrials.gov · NCT05607173 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Nov 18, 2021

    Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease · COMPLETED · sponsor: Sanofi · Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

    ClinicalTrials.gov · NCT05129241 (opens the source filing in a new tab)

  4. Trial

    PHASE2/PHASE3 registered

    Oct 21, 2019

    Thrombotic Thrombocytopenic Purpura · COMPLETED · sponsor: Sanofi · A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

    ClinicalTrials.gov · NCT04074187 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Oct 17, 2017

    Neoplasm Malignant · COMPLETED · sponsor: Sanofi · Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

    ClinicalTrials.gov · NCT03324113 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources